Lundbeck invests in Ossianix for neurological drugs

01/3/2012 | Reuters

Ossianix received a convertible promissory note from H. Lundbeck to help it develop biopharmaceutical agents for the central nervous system. Lundbeck has negotiation rights for certain medicines and technology resulting from the project. Separately, Lundbeck rolled out epilepsy treatment Onfi in the U.S.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC